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ABSTRACT 
Porcine circovirus type 2 (PCV2) is a pathogen of swine. Vaccines against PCV2 are 
available, although none are capable of differentiating infected from vaccinated animals (DIVA). 
Positive and negative DIVA markers were introduced in the vaccine constructs. Decoy epitopes 
were modified by site directed mutagenesis to avoid possible subversion of host immunity and 
achieve a rationalized vaccine design. Immunization of pigs with the modified vaccines, 
followed by challenge with a virulent field strain showed that the efficacy of the vaccine was 
comparable to a commercial vaccine. The average weight gain was significantly higher group 
vaccinated with experimental construct if compared to the group that received commercial 
vaccine.  An appropriate response to the positive and negative DIVA tags was detected. 
Therefore, the strategy used in this study is the first to enable a DIVA capable vaccine and 
accompanying immuno-assay, while using an epitope based approach to target improved 
immunogenicity.  
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LITERATURE REVIEW 
Porcine Circovirus 
Introduction 
Porcine circovirus strain 1 (PCV1) was first described in 1974 as a contaminant virus in a 
pig kidney cell line (PK-15) (Tischer et al., 1974). Porcine circovirus type 2 (PCV2) was first 
discovered in 1998 from the cases of post-weaning multi-systemic wasting syndrome (PMWS) 
(Ellis et al., 1998). Since then PCV2 has been identified as the causative agent of several 
associated clinical syndromes, now collectively designated as the porcine circovirus associated 
diseases (PCVAD). 
Post-weaning multi-systemic wasting syndrome (PMWS) was first described by Clark et 
al (Clark, 1997). It affected pigs at about 5-6 weeks of age. The main clinical signs of PMWS 
were wasting and dyspnea occasionally jaundice and reduced weight gain when compared to 
healthy pigs. It can also be accompanied with a loss of appetite and lead to emaciation and 
weakness. Lymphoid depletion, histiocytic replacement and enlargement of lymph nodes were 
noted as the hall-mark lesions of PMWS. The architecture of the lymph node is often disrupted 
(Opriessnig et al., 2007; Segalés, 2012). Mechanisms of lymph node depletion remains to be 
examined in detail but it was suggested that inhibition of cell proliferation leads to the observed 
depletion (Mandrioli et al., 2004). Inflammation of the liver, spleen, lung and intracellular 
inclusion bodies localized in the cytoplasm are commonly detected. The inclusion bodies were 
proven to be clusters of PCV particles (Harding and Clark, 1997). The lesions in the lymphoid 
system leads to immune suppression and increased risk of opportunistic infections.   
As described below, PCV2 was later found to induce other clinical manifestations that 
were not included in PMWS. So the more general classification as PCVAD was introduced 
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(Opriessnig et al., 2007; Segalés, 2012). The interest in this pathogen have been growing ever 
since (Figure 1). 
 
Figure 1. Absolute number of academic publications on the topics related to porcine circovirus. 
Considerable increase in the number if publications is observed after year 1998, when PCV was 
associated with Post Weaning Multi-systemic Wasting Syndrome (PMWS). Produced with Web 
of Science (Thomson Reuters, NY).  
 
The other manifestations of PCVAD incudes respiratory signs, reproductive disorders, 
enteric disease, diarrhea and the porcine dermatitis and nephropathy syndrome (PDNS) (Meng, 
2013).On a histological level, PCV2 associated enteric disease presents itself as inflammation of 
the enteric tract (Jensen et al., 2006). Enteric disease associated with PCVAD develops at 8-16 
weeks. Respiratory signs caused by PCV2 fall under the umbrella of the porcine respiratory 
disease complex (PRDC), which usually involves coinfections with other viruses and bacteria. 
Respiratory signs of PCVAD are usually observed at 8-16 weeks of age also. Signs can include 
dyspnea or difficulty in breathing and cough, which can further reduced weigh gain due to 
anorexia (Bolin et al., 2001). Reproductive disorders caused by PCV2 include increased 
probability of abortions, stillbirth and pre-weaning mortalities (Mikami et al., 2005). Porcine 
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Dermatitis and Nephropathy Syndrome (PDNS) can also be one of the signs of PCV2 infection. 
It manifests as an appearance of purplish red and slightly raised blotches of different shapes and 
sizes on the various parts of animal body, and sometimes pigs have difficulty breathing or appear 
depressed and reluctant to eat (An et al., 2007).  Hence, if unchecked, PCVAD can lead to a 
catastrophic decreases in the weight gain of production pigs and impose a significant pressure on 
the pork industry.  
PCV2 – Virus Classification, Structure 
Porcine circovirus type 2 is one of the smallest known viruses. Its non-enveloped 
icosahedral capsid is only 17 nm in diameter. The genome of PCV2 virus is a single stranded 
circular covalently closed molecule of DNA (ssDNA) about 1767 bases long; however different 
strains vary in exact length by a few base pairs. The circular nature of their genomes led to the 
naming the family Circoviridae. A number of other viruses are also classified in the Circoviridae 
family, such as Psittacine Beak and Feather Disease Virus, porcine circovirus type 1, pigeon 
circovirus, canary circovirus, goose circovirus and chicken anemia virus. While the chicken 
anemia virus belongs to the Gyrovirus genus, the other members are grouped under the 
Circovirus genus (Olvera et al., 2007). PCV1 and PCV2 was shown to infect human cell culture, 
but they were not found in the humans (Hattermann et al., 2004). Torque teno virus (TTV) that is 
present in healthy humans was for previously considered as a circovirus, but it was later 
reclassified.  
The genome of the virus is ambisense in that two main ORFs are on the opposite strands 
of the double stranded replicative form of the DNA. The origin of replication is located between 
the two major ORFs and it is presumed that it forms a hairpin loop (Mankertz et al., 1997). The 
two major viral proteins include the capsid protein (Cap) and the replicase protein (Rep), 
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encoded by the open reading frames (ORFs) ORF2 and ORF1 respectively. Other minor proteins 
such as ORF3, 4 and 5 whose function is to modify host’s cellular machinery and modulate 
immune response have also been reported (Liu et al., 2006, 2007; He et al., 2013; Lv et al., 
2015). Sequence identity between PCV1 and PCV2 ORF1 (rep) is 83%, while for ORF2 (cap) is 
67% (Constans et al., 2015a).The capsid is composed of 60 capsomeres and can be described as 
having T=1 symmetry.  
 
Figure 2. PCV genome and capsid. Schematic representation of the genome of PCV2 (A) that 
consists of two major ORFs. ORF1 encodes the replicase, ORF2 encodes the capsid protein. This 
ORF runs in an antiparallel manner. The origin of replication is located between the ORFs. Two 
dimensional representation of 3-dimentional model of Porcine circovirus capsid (Khayat,R. et 
al., 2011).  
 
The primary cell line for culturing PCV2 is PK15 epithelial cells from porcine kidney. 
There is no obvious cytopathic effect from viral infection; thus all operations that involve 
detection of virus infected cells are based on indirect immunofluorescence (IFA) or 
immunohistochemical assays. The viral genome can also replicate in a number of human cell 
lines upon transfection, however it is not clear if there is productive infection (Hattermann et al., 
2004). 
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Transmission and Global Distribution of PCV2 
Porcine circovirus is transmitted both vertically and horizontally. Horizontal transmission 
occurs through direct contact (Bolin et al., 2001), while vertical transmission occurs from the 
mother to the fetus. Infected animals are PCR positive from nasal swabs, oropharyngeal swab, 
and feces (Shibata et al., 2003). Vertical transmission was shown to occur in-utero from PCV2 
positive sows (West et al., 1999). Transmission via semen is also a possibility as viral DNA has 
been identified in semen of boars at 35 days post infection (Larochelle et al., 2000).  
PWMS and PCVAD is a global epizootic disease of swine. The virus is very infectious 
(Patterson and Opriessnig, 2010; Patterson et al., 2011) and can readily be spread from farm to 
farm. Hence, PCV2 is detected in a large proportion of farms globally. Since infection with 
PCV2 is not always manifested clinically, it can be subclinical. In the U.S about 54% out of 61 
sites were PCV2 positive (Shen et al., 2012). It was estimated that that PCVAD costs the EU 
swine industry €562-900 million per year (Alarcon et al., 2013). By other estimates PCVAD can 
lead to loss of $6 per weanling pig and $17 for each mating sow.  
Molecular Epidemiology Of PCV2 
Currently, there are 4 circulating PCV2 subtypes; PCV2a, b, c and d (or mPCV2b) 
(Figure 3 and 4). Until about 2008, the predominant subtype in the U.S was PCV2a. Following 
the introduction of commercial vaccines in 2006, a type-switching event resulted in PCV2b 
becoming the predominant subtype in the U.S, indicating that current commercial vaccines could 
induce selection pressure (Ssemadaali et al., 2015).  
PCV2a was the first described PCV2 subtype in the U.S. PCV2b  emerged later 
(Opriessnig et al., 2013) and  was associated with increased pathogenicity compared to PCV2a. 
PCV2c was identified in Denmark and is not highly prevalent or of remarkable pathogenicity 
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(Dupont et al., 2008).The latest of such newly emergent strains is PCV2d also referred to as the 
mutant PCV2b or mPCV2b in literature (Guo et al., 2010; Opriessnig et al., 2014a) (Figure 3 and 
4). Current vaccines in the U.S. are all based on PCV2a and they are still effective in prevention 
of clinical manifestation in herds that are infected with PCV2b (Opriessnig et al., 2014b).  
 
Figure 3. Phylogenetic representation of PCV2 subtypes. The evolutionary history was inferred 
by using the Maximum Likelihood method based on the Jukes-Cantor model (Jukes, 1969) . The 
tree with the highest log likelihood is shown. The percentage of trees in which the associated 
taxa clustered together is shown next to the branches. Total of 13 whole genome nucleic acid 
sequences 12 of which were previously described and PCV2b strain 41513 were analyzed. 
Nucleic acid sequence of PCV2b strain 41513 was used as backbone for the vaccine developed 
in this study, while mPCV2b strain was used as a challenge culture.  
 
However, the chance of emergence of a vaccine tolerant or more pathogenic, or more 
transmissible strain is present when multiple strains co-circulate in herds and infect the same 
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animal (Firth et al., 2009). Eradication of PCV2 from agricultural farms will reduce the 
possibility of viral evolution and the need to update vaccines and diagnostics. 
Vaccination against PCV2 is effective in prevention of clinical signs but does not prevent 
shedding of the virus or subclinical infection. Continuous circulation of virus under the selective 
pressure of vaccine- induced immunity could lead to the emergence of new strains that will have 
subtle antigenic difference from vaccine strain, leading to isolated cases of vaccine escape 
(Constans et al., 2015a). Indeed, it was estimated that mutation rate for PCV is among the 
highest for viruses that have DNA genomes, at 1.2 × 10−3 substitutions/site/year (Firth et al., 
2009). New emergent strains can vary in their biological properties, and they might have 
increased pathogenicity (Horlen, 2007).  
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Figure 4. Alignment of amino acid residue of ORF2 strains of different strains of PCV2. In the 
figure presented difference in amino acid residue composition between PCV2 strains is 
presented. PCV2b has a motif which distinguishes it from PCV2a located in the region between 
residues 85 and 102 (Cheung, 2009); while mPCV2b has additional changes at several positions 
such as 8, 53, 59, 63, 68, 78, 90, 134, 169, 210, 215, and the addition of a lysine residue in 
position 234. 
  
AF118097.2 PCV2a M T Y P R R R Y R R R R H R P R S H L G Q I L R R R P W L V  [ 30]
41513 PCV2b . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  [ 30]
KJ133547.1 mPCV2b . . . . . . . F . . . . . . . . . . . . . . . . . . . . . .  [ 30]
EU148503.1 PCV2c . . . . . . . . . . . . . . . . . . . . H . . . . . . . . .  [ 30]
AF118097.2 PCV2a H P R H R Y R W R R K N G I F N T R L S R T F G Y T V K R T  [ 60]
41513 PCV2b . . . . . . . . . . . . . . . . . . . . . . . . . . I . . .  [ 60]
KJ133547.1 mPCV2b . . . . . . . . . . . . . . . . . . . . . . I . . . . . K .  [ 60]
EU148503.1 PCV2c . . . . . . . . . . . . . . . . A . . . . S . V . . . N A S  [ 60]
AF118097.2 PCV2a T V T T P S W A V D M M R F K L D D F V P P G G G T N K I S  [ 90]
41513 PCV2b . . R . . . . . . . . . . . N I N A . L . . . . . S . P R .  [ 90]
KJ133547.1 mPCV2b . . R . . . . N . . . . . . N I N . . L . . . . . S . P L T  [ 90]
EU148503.1 PCV2c Q . S P . . . . . . . . . . N I N Q . L . . . . . S . P L T  [ 90]
AF118097.2 PCV2a I P F E Y Y R I R K V K V E F W P C S P I T Q G D R G V G S  [120]
41513 PCV2b V . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  [120]
KJ133547.1 mPCV2b V . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  [120]
EU148503.1 PCV2c V . . . . . . . . . . . . . . F A R . . . . . . . . . . . .  [120]
AF118097.2 PCV2a T A V I L D D N F V P K A N A L T Y D P Y V N Y S S R H T I  [150]
41513 PCV2b S . . . . . . . . . T . . T . . . . . . . . . . . . . . . .  [150]
KJ133547.1 mPCV2b . . . . . . . . . . T . . . . . . . . . . . . . . . . . . .  [150]
EU148503.1 PCV2c . . . . . N . . . . T . . T . . . . . . . . . . . . . . . .  [150]
AF118097.2 PCV2a P Q P F S Y H S R Y F T P K P V L D S T I D Y F Q P N N K R  [180]
41513 PCV2b T . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  [180]
KJ133547.1 mPCV2b T . . . . . . . . . . . . . . . . . R . . . . . . . . . . .  [180]
EU148503.1 PCV2c T . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  [180]
AF118097.2 PCV2a N Q L W L R L Q T S R N V D H V G L G T A F E N S K Y D Q D  [210]
41513 PCV2b . . . . . . . . . A G . . . . . . . . . . . . . . I . . . G  [210]
KJ133547.1 mPCV2b . . . . . . . . . T G . . . . . . . . . . . . . . I . . . .  [210]
EU148503.1 PCV2c . . . . M . . . . T G . . . . . . . . H . . Q . . T N A . A  [210]
AF118097.2 PCV2a Y N I R V T M Y V Q F R E F N L K D P P L N P *  [234]
41513 PCV2b . . . . . . . . . . . . . . . . . . . . . . . .  [234]
KJ133547.1 mPCV2b . . . . I . . . . . . . . . . . . . . . . . . K  [234]
EU148503.1 PCV2c . . V . . . . . . . . . . . . . . . . . . . . K  [234]
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Immune Response to Pcv2 Infection 
Cell Mediated Immunity 
Pathogens have an intricate relationship with the host’s immune system. PCV2 is not an 
exception to this rule. The two major arms of the immune response include cell mediated 
immunity (CMI) and humoral or antibody-mediated immunity. While the CMI against PCV2 is 
not very well characterized, PCV2 is known to infect dendritic cells (DCs), and persist in them 
without viral replication, induction of apoptosis, or antigen presentation. Since DCs are one of 
the most important MHC class II antigen presenting cells, their functional inactivation can be 
one of the mechanisms for immune evasion for the virus (Vincent et al., 2003). In addition, it 
was shown that PCV2 infected peripheral blood mononuclear cells (PBMC) showed reduced 
response to mitogens, ability of PBMS to produce INF- γ, IL-2 and IL-4 (Darwich et al., 2003). 
Infection of natural interferon producing cells (NIPCs) by PCV2 reduced their ability to produce 
IFN-α and TNF-α, thus preventing maturation of DCs (Vincent et al., 2007). The genome of 
PCV2 contains a number of interferon-stimulated response element (ISRE) like sequences. The 
role of these sequences was examined by site directed mutagenesis of the sequence, followed by 
infection of pigs with the mutated PCV2 alone or in a co-infection with the porcine reproductive 
and respiratory syndrome virus (PRRSV). The results indicated that the ISRE influenced PCV2 
pathogenesis (Ramamoorthy et al., 2011).  
The viral protein encoded by ORF3 was shown to induce apoptosis in-vitro through 
activation of caspace-3 and caspase-8 (Liu et al., 2005), and in-vivo in BALB/c mice. However, 
pigs that were inoculated with PCV2 that has a null mutation in ORF3 did not show reduction in 
lymphocyte count, nor did this virus showed histopathological effect on the lymph node (Liu et 
al., 2006). Similarly, in another in-vivo study on swine there were no significant differences in 
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either histological and gross lesions between wild type and ORF3 null mutant virus (Juhan et al., 
2010). As of now the role of ORF3 remains to be interrogated. Furthermore, the ORF4 protein 
was implicated in the negative regulation of ORF3 expression, thus down-regulating cellular 
apoptosis pathways (Gao et al., 2014). In this study mutants of PCV2 were created that had 
mutations either in the start or stop codon of ORF4. The results off this study were explained by 
competitive inhibition of transcription (Lapidot and Pilpel, 2006) or through codon pair bias 
(Kunec and Osterrieder, 2016) since there is no evidence that ORF4 product itself interacts with 
molecular machinery to inhibit the ORF3 expression.  Thus, despite its small genome size, PCV2 
possesses a repertoire of effects to modulate host’s immune response.  
Humoral Immunity 
In PCV2 infected animals, specific antibodies can be detected as early as 7 days post-
infection (DPI), with a maturing of the response between DPI 14-21(Beach et al., 2010, 2011). 
At least 3 proteins of PCV2 are known to induce seroconversion: ORF1, 2, 3 (Peng et al., 2016). 
Neutralizing antibodies to PCV2 are observed on DPI 14 (Meerts et al., 2006).  The best 
characterized predictor of clinical outcomes in PCV2-infected animals is the presence of 
neutralizing antibodies IgG to the capsid protein (Blanchard et al., 2003). Maternal antibodies 
can confer titer dependent protection against PCV2 infection, however such passive immunity 
does not confer absolute protection (McKeown et al., 2005; Ostanello et al., 2005). While 
controversial, it is largely accepted that maternal antibodies do not interfere with the 
development of vaccine induced immunity (Fort et al., 2008; Opriessnig et al., 2008a). Thus the 
induction of humoral immune responses against the capsid protein has been the primary focus 
vaccine development against PCV2. Additional information about antibody responses towards 
PCV2 is referenced throughout this thesis 
11 
Current PCV2 Vaccines 
Today, a number of commercial PCV2 vaccines are used in veterinary practice. They are 
all efficient in prevention of clinical manifestations of PCVAD. Existing vaccines are based on 
varying compositions of viral antigens. Whole inactivated PCV2 viral particles are used as an 
antigen in Circovac (Merial S.A.S., Lyon, France)(Ishikawa et al., 2008). Recombinant, 
baculovirus-expressed capsid protein is used for the formulation of the Ingelvac CircoFLEX 
(Boehringer Ingelheim, Ingelheim, Germany) (Roof et al., 2010),  Circumvent PCV2 
(Intervet/Schering-Plough Animal Health, Millsboro, USA)(De Grau et al., 2007) and Porcilis 
PCV2 (Intervet International BV, Boxmeer Netherlands)(Ruiz et al., 2008) vaccines. The 
Suvaxyn PCV2 vaccine (Fort Dodge Animal Health Limited, Southampton, United Kingdom) 
consists of a unique formulation of a chimeric PCV1-2 virus with the replicase gene from non-
pathogenic PCV1 and capsid gene from PCV2 (Connor et al.; Fenaux et al., 2004).  
Typically, piglets should be vaccinated at 3 weeks of age, and sows should be immunized 
with two doses three weeks prior to farrowing. Revaccination for sows is also recommended 
before each gestation. The ability of immunized sows to transfer immunity via the colostrum to 
the piglets is important for protection.  Immunization with the Circovac vaccine, which contains 
killed virus, is recommended twice with 3 weeks of time between the initial immunization and 
booster. Ingelvac CircoFLEX is unique in that it requires a single dose vaccination at three 
weeks, with the advantage that immunity is mounted earlier and labor cost is reduced. The 
Circumvent PCV2 and Porcilis PCV2 vaccines allow users to choose between single and double 
dose vaccination, although double dose is recommended. Circumvent PCV2 is unique in that it 
allows primary immunization as early as 3 days of age. Two dose schemes are recommended if 
piglets have a high level of maternal antibodies (European Medicines Agency, 2009). 
12 
A meta-analysis study conducted by Kristensen et al. summed up the results of 66 trials 
that tested vaccine efficacy against PCV2 (Kristensen et al., 2011). This meta-analysis indicates 
that all vaccines significantly increase average daily gain (ADG) when compared to 
unvaccinated animals. However, there is no significant difference in efficacy between individual 
vaccines. This study also revealed that presence of porcine reproductive and respiratory 
syndrome virus (PRRSV) in the herd reduce the effect of PCV2 vaccination; herds without 
PRRSV showed higher values of average daily weight gain (ADG). The presence or absence of 
PRRSV had no significant effect on the levels of mortality reduction due to vaccination of 
piglets in the trials (Kristensen et al., 2011). Vaccinated finishing pigs (post nursing period) 
showed an ADG of 41.5g, while the AFG in nursing pigs was only 10.6 g. This finding can be 
explained by the fact that in nursing pig a large part of protection is conferred by the maternal 
IgM and IgA antibody that is transferred in the milk. All vaccines studied reduced neonatal 
mortality by about 4-5%, thus improving cost effectiveness. Authors also mention that in 
individual trials only a small group of animals are vaccinated, while in case of commercial 
practice all animals are vaccinated, leading to increased protection due to herd immunity 
(Kristensen et al., 2011).  
While current vaccines are effective in reducing clinical signs by stimulating  immune 
responses to the capsid protein (Kristensen et al., 2011), they do not induce “sterile” immunity 
or, therefore, prevent viral evolution.  Additionally, there are no accompanying Differentiation of 
Infected from Vaccinated Animal (DIVA) assays for any of the commercially available vaccines, 
a key requirement for monitoring vaccine compliance or for future disease eradication efforts. 
The primary difference between a DIVA capable vaccine and regular vaccine is that the DIVA 
vaccine includes differential markers that are absent in wild type pathogen, e.g. deletion of a 
13 
viral antigen or insertion of a foreign antigen. An accompanying ELISA test will either not detect 
antibodies in the former case or detect antibodies to the foreign antigen in the latter case. 
Vaccines with the capability of differentiating vaccinated and infected animals enable the 
removal of infected animals from the population to eventually reach a disease free status. For 
example, the pseudorabies virus was eliminated due to utilization of marker vaccines that had 
glycoprotein E (gE) excluded from vaccine strain of PRV (Bech-Nielsen et al., 1995; Bouma, 
2005). Similarly, brucellosis is largely eliminated in the U.S due to systematic vaccination with 
the DIVA-enabled Brucella abortus RB51 strain in combination with the euthanasia of infected 
animals as detected by the DIVA immunoassay assay (Pappas et al., 2006). Therefore, the 
development of a DIVA-capable vaccine involves the addition of negative or positive 
identification markers to the vaccine, and an accompanying DIVA assay, usually an enzyme-
linked immunosorbent assay (ELISA).  
Current PCV2 vaccines do not have DIVA capabilities. Thus, they do not enable the 
removal of infected animals to produce PCV2 free farms. Even though vaccines are effective in 
reducing clinical signs, the PCV2 virus is still circulating as subclinical infections. Such 
circulation under constant selective pressure by vaccination may lead to the evolution of mutants 
which can escape vaccine induced immune responses (Ssemadaali et al., 2015). 
Epitope Analysis Of The PCV2 Capsid Protein 
The PCV2 capsid protein is typically 233 amino acid long. Four major immunogenic 
regions have been identified by several researchers in the PCV2 capsid protein (Mahé et al., 
2000; Truong et al., 2001; Lekcharoensuk et al., 2004) (Figure 5). When PCV2 viral particles 
were incubated with heparin, heparan sulfate, and chondroitin sulfate B, the glycosaminoglycans 
treated virus had reduced growth titers, when tested on 3D4/31 cells, indicating that a receptor-
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ligand interaction had occurred. Therefore, glycosaminoglycans are believed to be a potential 
receptor for PCV2. Further, PCV2 infects a broad range of cells and a heparan sulfate-binding 
motif XBBXBX (where B is a basic amino acid and X is a hydrophobic residue) is present in the 
PCV2 capsid. The putative receptor binding site was identified as spanning amino acid residues 
98-103, which are conserved among PCV strains (Meerts et al., 2006;Misinzo et al., 2006). It can 
be assumed that antibodies against this region will possess neutralizing properties as they can 
potentially block the virus-receptor interaction. 
The initial examination of immunogenic epitopes on the PCV2 capsid protein was 
conducted with the goal of differentiating it from PCV1.The study by Mahe et.al. revealed that 
the major antigenic regions of PCV2 Cap spanned residues 69-83, 117-131 and 169-183 (Mahé 
et al., 2000). Interestingly, in another study, the prevalence of sero-positive animals with PMWS 
to residues 117-131 increased from week 8-10 to week 16-19 from 38 to 69% indicated that this 
region is a marker for antibody responses in later stages of PCV2 infection or disease. It was also 
shown that 26% of the 406 animals studied from PMWS-free herds had detectible titers against 
the same epitope. Testing for antigen specificity by western blotting confirmed the specificity of 
the reaction with PCV2 (Truong et al., 2001).  A number of shorter PCV2 capsid specific 
epitopes were identified using a randomly generated phage library. However their neutralizing 
activity was not explored (Ge et al., 2013). In another study, analysis of linear epitopes identified 
residues 233 and 156 as important for virus neutralization (Lekcharoensuk et al., 2004; Shang et 
al., 2009). Bioinformatics prediction of B and T cell epitopes in the various PCV2 subtypes 
indicated that very subtle changes of 1-2 amino acids could affect the antigenic profile of the 
PCV2 capsid protein  (Constans et al., 2015a). 
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Figure 5. Previously described epitopes. Amino acids highlighted in pink immunogenic regions 
identified by Mahe (Mahé et al., 2000).  Amino acid residues highlighted in gold were identified 
by Shang (Shang et al., 2009). Epitopes identified by Trible et. al. as the most important amino 
acids in epitope 169-180 (Trible et al., 2011) are in emerald green.  
 
Antigenic epitopes that are highly immunogenic, but do not play a protective role in the 
neutralization of viral infectivity, are known as decoy epitopes. The presence of decoy epitopes 
in protective antigens is a mechanism of immune evasion that also diminishes vaccine efficacy. 
In 2011, Trible  et. al. identified the immunogenic region 169-180 of the capsid protein as a 
possible decoy epitope because pigs showing clinical signs of PMWS had high levels of 
antibodies to this region while pigs that did not show clinical signs did not (Trible et al., 2011).  
Truncation of the ORF2 protein followed by alanine scanning, a technique where each amino 
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acid residue in the span of 169-180 was sequentially substituted to alanine, resulted in the 
identification of residues 173,174,175 and 179 as key players. The identified amino acid residues 
are conserved among the PCV2 strains, indicating that they may possess an important biological 
function (Constans et al., 2015a).  
In the same study it was shown that at 3 week of age, the response towards peptide 169-
180 is almost as high as to the ORF2 antigen lacking the nuclear localization signal (residues 40-
233), but at 16 weeks of age this immune response is significantly diminished. In later functional 
studies, pigs were immunized with the ORF2 antigen (residues 40-233) or 169-180 peptide and 
challenged with virulent PCV2 virus (Trible et al., 2012). Pigs immunized with the 169-180 
peptide had total antibodies titers similar to that of the group that was immunized with the ORF2 
antigen (40-233). Surprisingly the serum from pigs that were vaccinated with peptide 169-180, 
was similar to non-immunized pigs in terms of neutralizing activity. Moreover, pigs that were 
immunized with 169-180 peptide had viral loads similar to the unvaccinated controls, while pigs 
immunized with the ORF2 antigen (residues 40-233) had no detectable viral loads. Interestingly, 
upon challenge with the virulent virus, the level of antibodies specific to the 169-180 peptide 
increased in pigs that were immunized with 169-180 peptide and non-immunized group, while in 
group that was immunized with ORF2 antigen (40-233) level of antibodies specific to 169-180 
peptide remained low. The pigs immunized with the oligopeptide 169-180 had the highest 
immuno-histochemisty (IHC) scores for post-challenge, PCV2 antigen detection in their lungs. 
The scores were even higher than non-immunized pigs (Trible et al., 2012). In totality, these 
results suggest that amino acids residues 169-180 of the ORF2 protein, while able to induce 
strong antibody responses, are not able to induce protective immunity. Amino acid residues 173, 
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174, 175,179 were particularly important, as was shown by alanine scanning and the fact that 
these residues are conserved among PCV2 strains. 
Immune Evasion Of Antibody Responses  
Protective epitopes are the epitopes which upon binding to corresponding antibodies lead 
to neutralization of viral particles and therefore viral infectivity. Protective epitopes are most 
often located near the virus receptor recognition site and are conserved (Köhler et al., 1994). 
Viruses have evolved to avoid the immune response by directing the immune response away 
from protective epitopes towards non-protective but immuno-dominant epitopes also called 
decoy epitopes. Decoy epitopes are defined as highly immunogenic epitopes, but their binding to 
the corresponding antibody does not lead to viral inactivation, and can potentially lead to 
antibody mediated immune evasion (Carme et al., 2009; Di Lorenzo et al., 2011; Diamond, 
2003).  Decoy epitopes are also often more variable than protective epitopes, as this allows for 
pathogen to more easily avoid the immune response. 
Based on the knowledge that initial repertoire of antibodies produced in the response to 
HIV-1 infection remains mostly unchanged later in infection, even when the virus undergoes 
antigenic variation Köhler et al. proposed the term deceptive imprinting (Köhler et al., 1994) to 
describe the phenomenon described above. Deceptive imprinting can be described as an 
emerging area of knowledge in host-pathogen interactions. The host’s immune response has a 
bias to the first immuno-dominant epitopes encountered. However, the pathogen can diverge 
under the pressure of host’s immune response to alter its antigenic properties. The evolution of 
the pathogen can occur inside the same host, as part of clinical or subclinical infections, as the 
case for HIV or caprine arthritis and encephalitis virus (CAEV) respectively, or in a non-species 
specific host as in the case of the influenza virus (Bianchi et al., 2005). Realization of the role 
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that deceptive imprinting plays in infection has led to the development of immune refocusing to 
channel the immune response towards protective immunity and avoid the immune bias towards 
non-protective correlates. 
Immune refocusing is therefore an approach where the rationality of vaccine design can 
be achieved through manipulation of epitopes (Tobin et al., 2008). For example, if epitopes that 
are variable throughout the serotypes of pathogen are excluded from vaccine, then animals will 
develop immune response only to epitopes that is conserved across the serotypes. In the same 
manner changes can be introduced in decoy epitopes in the vaccine construct, so that deceptive 
imprinting is avoided at time of challenge with the agent, so that the animal will presumably 
have higher titers of protective rather than non-neutralizing antibodies.  
For example, in the case of foot-and-mouth disease virus (FMDV) the main protective 
antigen is a capsid (VP1), which is highly variable. Analysis of hypervariable regions helped to 
identify conserved regions that would be most suitable for vaccine development leading to the 
development of effective vaccines (Tulasiram and Suryanarayana, 1998; Mayr et al., 1999; 
Cheevers et al., 2003; Lech et al., 2013). One important consideration for the rational design of 
vaccines is the surface localization of epitopes. In the native form of the antigen, some of the 
epitopes may not be exposed to the outside environment due to three dimensional folding. To 
identify whether a particular epitope is exposed or not, two approaches are available. The first is 
the examination of the three dimensional structure of the protein. This is often difficult because 
the structure of many viral antigens remained to be solved. Another approach would be to 
directly screen for antibodies to particular epitopes using sera from animals exposed to the agent. 
Linear epitopes can be mapped by PEPSCAN technology, while conformational epitopes can be 
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mapped by the interrogation of antigenic properties of truncated proteins with monoclonal 
antibodies. 
Objectives of This Thesis 
The primary goal of the current study is to enhance the functionality of existing PCV2 
vaccines by simultaneously improving their immunogenicity and introducing a DIVA capability. 
We have identified additional decoy epitopes and tested the premise that mutation of the 
identified decoy epitopes will result in enhanced antibody mediated immunity, when pigs are 
immunized with the altered proteins. Increasing the threshold of protection could likely prevent 
or reduce the evolution of new viral variants. The disease eradication potential of an improved 
vaccine will not only will relieve the farms of the burden of constant vaccination but also 
improve the life quality of the animals, so that we can enjoy bacon in our sandwiches with a 
slightly reduced sense of guilt. If eradicated, PCV2 would not have the chance to evolve into 
serotypes that would not be affected by vaccine induced immunity. Finally, to address the gap in 
the unavailability of DIVA PCV2 vaccines and enhance the performance of the improved 
vaccine, we have introduced a positive and negative DIVA marker in the rationally re-designed 
vaccine. This study is the first to describe an epitope- based approach to immunization against 
PCV2 in swine, while further validating the ”immune-refocusing” approach to vaccine 
development (Tobin et al., 2008).   
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IMMUNOGENICITY OF A PORCINE CIRCOVIRUS STRAIN 2 CAPSID PROTEIN 
WITH MUTATED IMMUNO-DOMINANT DECOY EPITOPES AND DIVA 
CAPABILITIES 1 
Abstract 
Porcine circovirus type 2 (PCV2) belongs to the Circoviridae family and is an important 
pathogen for swine industry as cause of porcine circovirus associated diseases (PCVAD). While 
several effective commercial vaccines against PCV2 are available, none of them are capable of 
differentiating infected and vaccinated animals (DIVA). Moreover, all target the PCV2a strain 
that has been replaced by PCV2b in the U.S since 2007. Furthermore, while current vaccines are 
effective, new virus variants continue to emerge, indicating that vaccine induced selection 
pressure could trigger viral evolution in the field. 
To develop a rationally designed, improved PCV2 vaccine with the ability to differentiate 
vaccinated and infected animals (DIVA), positive and negative DIVA markers were introduced 
in the vaccine constructs. In addition, decoy B cell epitopes that can divert the protective 
antibody responses towards non-protective regions of the vaccine antigen, were modified by site 
directed mutagenesis to avoid possible subversion of host immunity and achieve a rationalized 
vaccine design. Immunization of pigs with the modified vaccines, followed by challenge with a 
 
1 The material in this chapter was co-authored by Oleksandr Kolyvushko, Brett Webb, Angela 
Pilatzki, Marcia Ilha, Peter Nara, Diel Diego, Steve Lawson, Eric Nelson, and Sheela 
Ramamoorthy. Oleksandr Kolyvushko had primary responsibility for design and preparation of 
vaccine samples, establishing assay required for this work and analysis of vaccine efficacy and 
DIVA capabilities. Oleksandr Kolyvushko was one of the primary developer of the conclusions 
that are advanced here. Oleksandr Kolyvushko also drafted and revised all versions of this 
chapter. Sheela Ramamoorthy served as proofreader and was responsible for  the statistical 
analysis conducted and experimental design. Brett Webb, Angela Pilatzki, Marcia Ilha, Peter 
Nara, Diel Diego, Steve Lawson And Eric Nelson were crucial for animal study. 
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virulent field strain showed that the efficacy of the vaccine was comparable to a commercial 
vaccine. The average weight gain was significantly higher than that observed with the 
commercial vaccine.  An appropriate response to the positive and negative DIVA tags was 
detected. Therefore, the strategy used in this study is the first to enable a DIVA capable vaccine 
and accompanying immuno-assay, while using an epitope based approach to target improved 
immunogenicity.  
Introduction 
Porcine circovirus type two (PCV2) is a small virus with a single stranded circular DNA 
genome. It is the causative agent of porcine circovirus associated disease (PCVAD), an 
important disease of swine in agricultural settings across the world (Alarcon et al., 2013). 
Postweaning multisystemic wasting syndrome (PMWS) is the primary manifestation of PCVAD 
in weanling piglets (Clark, 1997). Clinical signs of PMWS include wasting, dyspnea and 
jaundice. Other syndromes caused by PCV2 include the porcine respiratory disease complex 
(PRDC), dermatitis and nephropathy syndrome (PDNS), reproductive disorders, 
lymphadenopathy, and enteritis. PCV2 is widely present on commercial farms as well as in wild 
swine population (Larochelle et al., 2000; Reiner et al., 2010; Schmoll et al., 2008; Vicente et al., 
2004).  
The PCV2 infectious viral particle consists of 60 subunits of the capsid protein encoded 
by the viral open reading frame 2 (ORF2). While little is known about cell mediated immunity to 
PCV2, neutralizing antibodies to the capsid protein (Cap) are a reliable predictor of protective 
immunity in the case of PCV2 infection (Meerts et al., 2006). Binding as well as neutralizing 
antibody in infected or vaccinated animals can be detected as early as 14-21 days post infection 
(DPI) (Beach et al., 2010, 2011; Meerts et al., 2006).  
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Currently, there are 4 circulating PCV2 subtypes; PCV2a, b, c and d. Until about 2008, 
the predominant subtype in the U.S was PCV2a. Following the introduction of commercial 
vaccines in 2006, a type-switching event resulted in PCV2b becoming the predominant subtype 
in the U.S, indicating that current commercial vaccines could induce selection pressure 
(Ssemadaali et al., 2015). However, a number of commercial PCV2 vaccines that effectively 
reduce or prevent clinical signs are available. They primarily target the PCV2a capsid protein 
and they are effective in preventing or reducing clinical manifestations of PCVAD (Kristensen et 
al., 2011) through formation of immune response to capsid protein. However, they do not 
prevent viral evolution.  Additionally, there are no accompanying Differentiation of Infected 
from Vaccinated Animal (DIVA) assays for any of the commercially available vaccines, which is 
a key requirement for monitoring vaccine compliance or for future disease eradication efforts. 
The DIVA strategy usually consists of a vaccine, and accompanying assay, usually an ELISA. 
Difference between a DIVA capable vaccine and regular vaccine is that DIVA vaccines include 
differential markers that are absent in wild type pathogen. Presence or absence to differential 
markers will be detected with accompanying ELISA test, and allow the differentiation of 
vaccinated from infected animals to enable the removal of infected animals from the population 
and disease eradication.  
Currently PCV2 imposes a huge financial burden on the industry and it decreases life 
quality of animals. Continuous viral circulation in animal farms may lead to emergence of new 
strains, potentially with higher pathogenicity. Epitope analysis of the PCV2 capsid protein by our 
group and others indicate the presence of 4 major immunodominant regions (Mahé et al., 2000). 
Recently, Trible et al., described a decoy epitope at positions 169-181 on the viral capsid protein 
(Trible et al., 2011). When taken in conjunction with the finding that neutralizing antibody 
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responses against PCV2 are only detected about 3 weeks post infection, in this study, we have 
explored the hypothesis that additional decoy epitopes may be present on the PCV2 capsid 
protein. In addition we have tested the premise that mutation of the identified decoy epitopes will 
result in enhanced antibody mediated immunity, post-immunization with the altered proteins. 
Finally, to address the gap in the unavailability of DIVA vaccines, we have introduced a positive 
and a negative DIVA marker in the rationally re-designed vaccine. This study is the first to 
describe an epitope based approach to immunization against PCV2 while further validating the    
”immune-refocusing” approach to vaccine development (Tobin et al., 2008). With the changes to 
decoy epitopes suggested in this study the resulting vaccine will presumably improve 
immunogenicity thus reducing the probability of negative clinical outcomes.  Having a vaccine 
with a corresponding DIVA assay, will allow assessment of vaccine compliance, and detection 
of the vaccine escape cases. The DIVA capability will allow for early isolation of vaccine escape 
cases, thus reducing viral circulation and reducing potential for emergence of new strains of 
PCV2. Combination of a DIVA capable vaccine and appropriate DIVA test will potentially lead 
to rational protocols for the eradication of PCV2 from animal farms.  
Material and Methods 
Mapping of neutralizing and decoy epitopes in the PCV2 capsid protein 
Two complimentary approaches were used to map the protective and decoy epitopes on 
the PCV2 capsid protein. For the first approach, based on the premise that early antibody 
responses will target non-neutralizing epitopes while later responses will target the protective 
epitopes. Archived sera collected at days post infection (DPI) 7 and 28 from PCV2 infected 
animals (Ramamoorthy et al., 2011) were used to perform a PepScan analysis of the PCV2a 
capsid protein.  Overlapping 12-mer peptides with a 9 residue overlap, spanning the entire capsid 
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protein were purchased from a commercial source (Mimotopes, Victoria, Australia).  To perform 
the peptide ELISAs, 100µl of a 10ug/ml solution of biotinylated peptides were bound to 
streptavidin coated ELISA plates. After blocking with 2% BSA and skimmed milk powder, 100 
µl of a 1:50 dilution of serum was reacted with the peptides in duplicate. Specific reactivity was 
detected by anti-swine IgG labeled with Horseradish peroxidase (HRPO) conjugate at a 1:2000 
dilution. The average of the lowest quartile OD values from each data set plus two standard 
deviations was subtracted from the final readings. Each corrected value was then expressed as a 
signal/negative [S/N] ratio with the corresponding value from the negative control data set. 
Values above an S/N ratio of 1 were considered positive.  
Mapping of neutralizing and decoy epitopes in the PCV2 capsid protein by a fluorescent focus 
inhibition assay 
To confirm the findings of the PEPSCAN analysis using the   second approach, pools of 
equal quantities of 5 peptides, spanning the previously defined immunogenic regions 
(Lekcharoensuk et al., 2004; Mahé et al., 2000) were used in peptide binding fluorescent focus 
inhibition assay to map which epitopes are protective (responsible for binding with neutralizing 
antibodies) and which may be decoy epitopes. Serum collected at DPI 28 because it would 
represent a mature immune response. Briefly, 10 ul of each of 5-6 selected peptides [1mg/ml] 
was pooled. 10 ul of each pool was incubated with 1:2 dilution of heat inactivated pooled DPI 28 
PCV2a anti-serum for 60 mins at 37oC. PCV2a strain 40895 with a titer of 104.5 TCID50/ml 
(Tissue culture infectious dose 50%)  was diluted 1:10 in DMEM. Equal volumes of diluted virus 
and peptide blocked antiserum were incubated at 37oC for 60 mins before layering on PK-15 
monolayers in 8 well chamber slides. Supernatants were removed after 3 hours and replaced with 
2% DMEM. Slides were stained with a PCV2 monoclonal antibody and anti-mouse FITC after 
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36 hours.  The number of PCV2 specific fluorescent foci in each well was counted as blinded 
evaluations by two individuals in two independent experiments with 4 replicates for each peptide 
pool. The mean value is presented as the percentage change in the treatment group when 
compared to the unblocked PCV2 antiserum collected at DPI 28. A non-specific swine influenza 
virus (SIV) peptide and negative DPI 0 serum pool were used as controls.  
Cloning of the PCV2b capsid protein with mutated decoy epitopes 
Using the ORF2 sequence of a previously cloned and sequenced PCV2b genome 
(Constans et al., 2015a), codon optimized template DNA was commercially synthesized 
(Eurofins Genomics, Louisville, KY) for cloning and bacterial expression. To introduce a 
negative DIVA marker, the nuclear localization signal (NLS) (1-39 amino acid residues) was 
omitted from the template DNA. To prepare the construct (designated as construct A), the coding 
sequence was modified to incorporate 5 single amino acid changes located in potential decoy 
regions Fig 6 and 7)  
 
 
Figure 6. Construction of the vaccine candidates. Schematic representation of the construction of 
vaccine candidates constructs A and B. NLS- Nuclear localization signal. Gra6- 20aa long 
epitope tag from Gra6 protein. (Gly)8- is a 8 glycine linker.  
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 Figure 7. Alignment of wild type ORF2 with constructs A and B. Changes that were introduced 
are highlighted with a blue box. NLS was replaced with GRA-6 tag, following by 8xGlycine 
linker and furin cleavage site. Construct 2 has 5 additional single amino acid changes: E104D, 
T131N, A133S, Q175N, and K179S. The commercially synthesized sequence containing 
restriction sites for XhoI and EcoRI (NEB, Ipswich, MA) was digested with the appropriate 
enzymes ((NEB, Ipswich, MA). and directionally cloned into a pET 28 vector (Novagen 
Darmstadt, Germany) to produce pre-construct A.   
 
A second construct (designated as construct B), that in addition to the four amino acid 
changes, six other amino acid residues (positions 170-175) within a decoy epitope previously 
identified by Trible et al (Trible et al., 2011) deleted, was prepared by overlap extension 
polymerase chain reaction (SOE-PCR) from construct A. The SOE-PCR was performed in two 
steps. Step one started with initial denaturation at 95°C for 5 min, followed by 25 cycles of 95°C 
for 1 min, 55°C for 30 secs, 72°C for 30 sec, final extention 72°C for 2 min with Phusion High-
Fidelity DNA Polymerase master mix (NEB, Ipswich, MA). Step one was carried out in two 
separate reactions, each of them had corresponding pair of primers 1-2 and 3-4 (Primer 
sequences were as follows: 1) 3’- GACTGAATTCCGTAAAAACGGTA-5’ 2) 3’- 
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GAGTTGTTCGGAGAGTCCAG-5’ 3) 3’- CTGGACTCTCCGAACAACTC-5’ 4) 3’- 
GCTACTCGAGTTACGGGTTCAGCG-5’). The amplified products were subjected to gel 
electrophoresis to verify the correct size and extracted from the gel with QIAquick Gel 
Extraction Kit (Qiagen, Hilden, Germany). The second step of SOE-PCR was performed in 
similar conditions as step one, except with 30 instead 25 cycles using primer 1 and 4. SOE-PCR 
reactions were performed using Phusion High-Fidelity DNA Polymerase (NEB, Ipswich, MA). 
Both sequences A and B were directionally cloned in to pET28a (Novagen Darmstadt, Germany) 
bacterial expression vector. The integrity of the construct was verified by sequencing and 
restriction digestion.  
Introduction of a positive DIVA marker 
Constructs A and B were then modified by inserting a positive DIVA marker. The Q5 
Site-Directed Mutagenesis Kit (NEB, Ipswich, MA) was used according to manufacturer’s 
instructions to introduce a DNA sequence that encoded a 20 amino acid long peptide from the 
GRA6, protein of Neospora caninum, an apicomplexan parasite which does not infect swine 
(Figure 3) together with a Glycine linker ((Gly) x8) and a furin proteolysis site. In short, a two-
step PCR reaction was used. Initial denaturation 98°C for 2 min, followed by 98°C for 2 min and 
25 cycles of 72°C for 30 sec and 72°C for 140 sec, final extension step was 72°C for 2 min. The 
following primer were used in final concentration of 0.5mM: Forward: 3’-
CGTTATTGCCGGCATCATTGCCGCCACCGTCACCAGATGGTTCC 
GGAGGGAATTCGGATCCGCG-5’, reverse: 3’- CGGGCAACGGTGGCGGCGGTGGT 
GGCGGTGGCCTGCGCACTAAACGTTTTCGTAAAAACGGTATC -5’   Site direct 
mutagenesis PCR reaction was carried out with Phusion High-Fidelity DNA Polymerase (NEB, 
Ipswich, MA). 
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One µl of PCR reaction mix was used in KLD (Kinase-Ligase-DpnI) reaction following 
the manufacturer’s instructions. The reaction mix consisted of 1µl of PCR product, and 5µl of 2x 
KLD buffer, and 1 µl of KLD enzyme mix, and was incubated for 10 minutes at room 
temperature. This KLD reaction mix was used to transform competent Top-10 cells (Thermo 
Fisher Scientific, Waltham, MA). The accuracy of the sequence of constructs A and B was 
confirmed by sequencing (Eurofins Genomics, Louisville, KY).  
Expression and purification of the construct A and B 
For bacterial expression, BL21 (DE3) (Thermo Fisher Scientific, Waltham, MA) cells 
were transformed with plasmids encoding constructs A and B according to the manufacturer’s 
instructions. Freshly transformed cells were grown overnight in 2000 ml of LB with 50 µg/ml of 
kanamycin. An overnight culture was used to inoculate the expression culture. Bacterial 
expression was induced when the OD630 reached 0.4 with 1 mM IPTG. Cells were collected at 6 
hours post induction by centrifugation at 6000 g at 4°C for 15 minutes with Avanti® J-26 XP 
Centrifuge (Beckman Coulter, Brea, CA) with a fixed angle rotor J-LITE® JLA-16.250 
(Beckman Coulter, Brea, CA ).  
The cell pellets were lysed in a binding buffer (8M Urea, pH=8.0, Imidazole 10mM, 
100mM sodium phosphate monobasic, 10mM TRIS) with sonication on ice at 30% amplitude 
until the solution became transparent. The total cell lysate was incubated with 2 ml of Ni-NTA 
(Qiagen, Hilden, Germany) agarose beads for 1 hour with rotation at RT and applied to a gravity 
flow column. Agarose beads on the column were washed with 10 column volumes of wash 
buffer (pH=6.3, 50mM Imidazole, 100mM sodium phosphate monobasic, 10mM TRIS). Specific 
protein was eluted with 5 column volumes of Elution buffer (pH=4.5, 250mM imidazole, 
100mM sodium phosphate monobasic, 10mM TRIS), 2 ml fractions were collected. The eluted 
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fractions were precipitated with 9 volumes of ethanol that was cooled down to -20°C. The 
mixture was incubated overnight at -20°C. Precipitated protein was pelleted with centrifugation 
at 10000 RCF for 30 minutes at 4°C with Avanti® J-26 XP Centrifuge (Beckman Coulter) with a 
fixed angle rotor J-LITE® JLA-16.250 (Beckman Coulter). Supernatant was carefully discarded 
and pellet was air dried. When pellet became dry it was re-suspended with 1x Tris-Glycine-SDS 
Running Buffer (Boston BioProducts). Purified proteins were stored at -80°C for vaccine 
formulation and were analyzed by western blotting, with anti-PCV2 and anti-N. caninum 
antibodies.  
Validation of the vaccine constructs by Western blotting 
SDS-PAGE was performed using a 12% polyacrylamide gel, in a Mini-PROTEAN 
Electrophoresis System (Bio-Rad, Hercules, CA). Prior to transfer, a PVDF membrane was 
submerged in methyl alcohol, and then incubated in transfer buffer (Boston BioProducts). Trans-
Blot SD semi-dry transfer cell (Bio-Rad, Hercules, CA) was ran at 10V  for 30 for transfer. 
Following the transfer, the membrane was washed 3 times with PBST. The membrane was 
blocked for 1 hour with 3% dry non-fat milk in PBST on a rotary shaker at RT. Primary 
antibodies was added at dilution of 1:250 in PBST, and incubated for 1 hour with gentle rotation. 
The membrane was washed 4 times with PBST at 5 minute each. Secondary HRPO labeled 
antibody was added at dilution of 1:1000 in PBST and incubated for 1 hour. The membrane was 
washed 4 times with PBST for 5 minute each and developed using TMB (Thermo Fisher 
Scientific, Waltham, MA). 
Cloning and expression of the DIVA markers as capture antigens for the DIVA ELISA 
For use as capture antigen for the DIVA ELISA, the NLS region of the ORF2 and N. 
caninum derived GRA6 tag were cloned into plasmid pET28 A Briefly, primers 3’- GCT 
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AGAATTCACCTACCCGCGTCGT-5’ and 3’- CGATCTCGAGTTAACGACGCCA 
ACGGTAACGGT-5’ were used to amplify the 117bp NLS sequence, Cloning into the pET-28a-
sumo vector was achieved using EcoRI and XhoI (NEB, Ipswich, MA) restriction enzymes. The 
DNA sequence from GRA6 gene that represents amino acid residues spanning from 179 to 197of 
the 232 long protein were codon optimized and cloned into the pET-28a-sumo bacterial 
expression vector using Q5 Site-Directed Mutagenesis Kit and primers 3’- GCAA 
TGATGCCGGCAATAACGCGGGCAACCTCGAGCACCAC-5’and 3’-CGCCACCG 
TCACCAGATGGTTCCGGAGGGAATTCGGATCC-5’, as described earlier.  Both constructs 
were subjected to restriction digestion and sequences were verified .Verification of protein 
expression by western blotting was carried out as described above with a swine anti-PCV2 serum 
for the NLS construct and a rabbit, polyclonal anti-N. caninum serum (provided by Dr. David 
Lindsay, Virginia Tech) for the GRA6 protein. Purification of the diagnostic proteins was carried 
out essentially as described above, except that the native purification system was used for the 
Gra6-sumo protein. Native purification was performed with a His-Spin Protein Miniprep (Zymo 
Research, Irvine, CA) following the manufacturer’s instructions. 
Preparation of the PCV2 challenge culture 
The cloned genome of mPCV2b strain (JX535296.1) was kindly provided as a 
monomeric copy in the TA cloning vector pCR2.1 (Thermo Fisher Scientific, Waltham, MA) by 
Dr. X.J. Meng, Virginia Tech and Dr. Tanja Opriessnig, The University of Edinburgh.  The 
genome was dimerized as previously described into the plasmid pBlueScript II SK (+)  (Fenaux 
et al., 2002), such that two tandem copies of the genome were inserted . Expression of the 
recombinant virus was verified by an immunofluorescence assay, as previously described 
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(Constans et al., 2015a). The titer of resulting virus culture was obtained as a TCID50 value in 
PK15 cells using Immunofluorescence assays. 
Formulation of the vaccine 
After adjusting concentration of the purified proteins for construct A and B to 1mg/ml, 
the proteins were individually mixed with an adjuvant MONTANIDE ISA 201 VG (Seppic) 
(Montanide, Fairfield, NJ) following the manufacturer’s instructions. In short, the protein 
solution was mixed 1:1 with adjuvant solution, for 2 hours at 31°C, with gentle shaking. The 
water-in-oil-in-water emulsion was transferred to 4°C right away until further use  
Testing of the vaccine in pigs 
Thirty-one five week old pigs were randomly divided in to 5 groups as follows: Group 1- 
unvaccinated controls (N=7), Group2 - Positive controls were administered a commercial 
vaccine following label instructions (Merial, Duluth, GA) (N=7) , Group 3– Con A ( 2ml dose, 
1ml i/m, 1ml S/C) (N=7), Group 4 – Con B ( 2ml dose, 1ml I/M, 1ml S/C) (N=7) Group 5 – 
Negative controls (N=3). Animals were boosted on DPV 18 by the same dose and route. Serum 
samples were collected on days post vaccination (DPV) 0, 11, 18, 25, 32, 42 and 53. At DPV 32 
all animals were challenged with 4ml of 105 TCID50/ml mPCV2d virus. Temperature and 
weights were measured at the day of challenge (DPV32), at DPV 38, 42, 47, and at the end of the 
experiment. At DPV 53 animals were euthanized. Gross lesions were assessed at necropsy. 
Tissues were fixed in 10% buffered formalin for 48 hours then transferred to 70% ethanol before 
being sectioned and routinely processed.  5µm thick sections of lung, tonsil, liver, kidney, 
spleen, tracheobronchial lymph node, mesenteric lymph node and thymus were prepared. 
Immunohistochemistry (IHC) was performed at the South Dakota State University Animal 
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Disease Research and Diagnostic Laboratory.The amount and in intensity of staining was scored 
on a 1-4 scale by a board certified pathologist who was blinded to the treatments.  
ELISA for the detection of binding antibody responses 
Antigens were diluted to final concentration of 400 ng/ml in carbonate coating buffer.  50 
ul was added to the 96 well high binding plates and incubated overnight. The following proteins 
were used as antigens on the ELISA: the complete ORF2 protein was prepared by in-vitro 
transcription and translation TnT® Quick Coupled Transcription/Translation System (Promega, 
Madison, Wisconsin, USA), the DIVA marker antigens for the NLS and GRA-6. Plates were 
washed 4 times with PBST and blocked with 100 ul of general block (ImmunoChemistry 
Technologies, Bloomington, MN) for 2 hours with shaking at 37°C. Plates were washed 4 times 
with PBST. The test serum was added at a dilution  of 1:50 and incubated for 2 hours. Plates 
were washed 4 times with PBST. Secondary anti-swine HRPO labeled antibodies were added at 
dilution 1:5000 and incubated for 1 hour. Plates were washed 4 times with PBST and developed 
using 50ul of SureBlue TMB (KPL, Gaithersburg, Maryland). The reaction was terminated with 
50µl of 1M HCl. OD450 was measured with ELx800 Absorbance Reader (Biotek, Winooski, VT). 
Fluorescent focus inhibition assays to detect virus neutralization 
Virus cultures for PCV2b strain 41513 (accession no. KR816332) (Constans et al., 
2015b) was rescued from the infectious clone as described above. The titer of the culture was 
adjusted to 103.7 TCID50/ml. Equal volumes (50 µl) of pooled pre-challenge serum (DPV 32) 
from each group and homologous PCV2b virus culture was incubated for 1 hour at 37 °C. The 
virus-serum solution was layered on PCV2 negative PK-15 cells and incubated for 1hr at 37oC, 
in four replicates. Four wells were infected with virus alone. The inoculum was removed, cells 
were washed twice and left in DMEM with 2% FBS. After 36 hours post inoculation cells were 
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fixed and stained with PCV2 specific antibodies as described above in the IFA section. The 
number of PCV2 specific foci in each well was enumerated by two independent operators. The 
reduction in the number of foci in wells with serum, indicating virus neutralization, was 
calculated as percentage reduction in number of PCV2 specific fluorescent foci compared to the 
virus controls. 
Detection of viral loads by qPCR 
Quantification of the viral loads in the pre and post-challenge sera collected at day 10 and 
day 17 post-challenge was assessed by qPCR. Total genomic DNA was extracted from the test 
sera with the Qia Amp DNA mini kit (Qiagen, Valencia, CA) and eluted into 100 µl of H2O. The 
qPCR reaction was essentially performed as described earlier (Opriessnig et al., 2003) with 
following modifications: only 1ul of extracted DNA from serum was used for qPCR. A primer 
concentration of 0.4 µM, probe concentration of 0.1uM, and Tm of 65°C was used with the 
QuantiFast Probe PCR Kit (Qiagen, Hilden, Germany) and CFX96 Touch (Bio-Rad, Hercules, 
CA) qPCR thermocycler.  
Statistical Analysis 
 Statistical analysis of data was performed in Minitab software (Minitab, State College 
PA) or on Microsoft Excel. Date collected was analyzed using multivariate analysis of variance 
(ANOVA) with significance value of p≤0.05. The Tukey method was applied for multiple 
comparisons. Differences in weight gain and viral loads were assessed by a Student T test. 
Results 
Mapping of neutralizing and decoy epitopes in the PCV2 capsid protein by PEPSCAN analysis  
Epitope mapping indicated that the initial (DPI 7) immune response targets peptides 19-
22, 33-38, 45-46 (Fig. 1). These results indicate the presence of immune-dominant and likely 
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non-protective epitopes at these locations due to the strong immune response to these regions in 
early post-infection sera with low neutralizing antibody levels.  On the other hand, the mature 
immune response (DPI28) shifted towards peptides 21-25, 33-44, 56-59, and 72-75, indicating 
the presence of neutralizing epitopes in these regions. 
 
Figure 8. PepScan analysis of the PCV2a capsid protein. PepScan analysis of the PCV2a capsid 
protein. Was performed using pooled sera from PCV2a infected pigs collected at DPI 7 and 28 
against a PCV2 ORF2 12-mer peptide library. Average corrected values are expressed as a 
signal/negative [S/N] ratio with the corresponding value from the negative control data set. 
Values above an S/N ratio of 1 [solid bar] were considered positive. 
 
Mapping of Neutralizing And Decoy Epitopes In The Pcv2 Capsid Protein By A Fluorescent 
Focus Inhibition Assay  
To further confirm which epitopes are responsible for protection, peptides were incubated 
with serum from DPI 28, which had a virus neutralization titer of 1:68. Peptide binding 
fluorescent focus inhibition assay revealed that peptides 33-38, and 45-46 resulted in a reduction 
of the number of specific fluorescent foci by about 50 and 15 percent respectively, while peptide 
19-22 had no appreciable effect.  Therefore, the regions spanned by the peptides mentioned 
above were hypothesized to contain immunodominant, non-neutralizing epitopes.  
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Figure 9. Peptide binding fluorescent focus inhibition assay to map protective and decoy 
epitopes. Pools of 4-6 peptides were incubated with DPI 28 PCV2 antiserum. Blocked antiserum 
was challenged with live virus. Blocking of neutralization activity was assessed as the number of 
PCV2 specific fluorescent foci in cells incubated with the blocked serum/virus mixture. Each 
well was blindly evaluated by two individuals in two independent experiments with 4 replicates 
for each peptide pool. The mean value is presented as the percentage change in the treatment 
group when compared to the unblocked DPI 28 PCV2 antiserum, with a decrease in the number 
of foci indicating decoy properties of that region and vice versa 
 
Cloning and Expression Of The Pcv2b Capsid Protein With Mutated Decoy Epitopes  
Sequencing of the cloned plasmid DNA encoding Con A and B indicated that desired 
mutations were intact, that the amino acid residues 170-175 were deleted in construct B, and that 
the introduction of the GRA-6 tag with linker ((Gly) x8) and furin proteolysis site was 
successful.  Western blot analysis (Fig 4) indicated that desired constructs reacted with both anti-
PCV and anti-Neospora antibodies, suggesting that GRA-6 tag and PCV2 part of protein both 
expressed correctly and d appropriate antigenic properties. 
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Figure 10. Analysis of proteins A and B. SDS-PAGE (A), Western blot with anti-PCV2 (B) and 
anti-Neospora(C) polyclonal antibodies. Both proteins A and B reacted well with both anti-
PCV2 and anti-Neospora antibodies with molecular weight about 30 kDa as expected.  
 
Expression of the DIVA antigens  
The bacterial expression constructs for the NLS and GRA-6 had the expected sequence. 
As expected, western blotting of the purified NLS protein the PCV2 antiserum showed the 
presence of an approximately 20 kDa band in both cases. Similarly, the purified GRA6 protein 
reacted specifically with the anti-N. Caninum antiserum at the expected molecular weight of 
approximately 20Kd (Figure 11).  
Preparation of the Pcv2 Challenge Culture  
The dimerized infectious clone of mPCV2b was created and confirmed by sequencing. 
The immunofluorescence assay showed the expression of apple green nuclear fluorescence 
typical of PCV2 infection (Figure 12).  The virus culture with a titer of 1x105 TCID50 was 
obtained and used to challenge the vaccinated pigs. 
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Figure 11. Expression of the DIVA antigens. Western blot image of A) purified Gra6 protein 
reacted with rabbit anti-neospora serum. B) Purified NLS protein reacted with swine anti-PCV2 
serum. Both proteins were detected at the expected molecular weight of approximately 20 kDa 
 
 
Figure 12. Immunofluorescent analysis of cells transfected with the dimerized infectious clone 
of mPCV2b. From left to right, cell nucleus stained with DAPI, anti-PCV2 antibodies stained 
cells showing recombinant viral particles and nuclear fluorescence, overlay of the DAPI and 
antibody stained images showing nuclear fluorescence specific to PCV2.  
 
Average Weight Gain Measurements 
 The average weight gain between the day of challenge and necropsy for group 1, 2, 3, 4 
was 25.3, 26.0, 26.8, and 31.5lb respectively (Fig 9). The pigs in group 4 gained an average of 
5.5lb more compared to the other groups. The difference in weight gain between pigs 
administered Con B and the unvaccinated pigs was statistically significant with a p=0.04.  
A B 
20 kDA 
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Figure 13. Average weight gain in the treatment groups. The weight of each pig was measured 
in pounds on the day of challenge and necropsy.  Mean values of the weight gain in pigs from 
each group (N=7) and the standard deviations are depicted.  * p≤0.05 as determined by a Student 
T test. 
 
Bodily Condition Measurements  
Of animals varied from slightly thin to slightly overweight but most of the animals had 
ideal score of 3(Cutler, 2014).  The unvaccinated animals experienced a slight loss of bodily 
condition 5 days after challenge but this loss was not significant, indicating that the challenge 
strain was not virulent enough to cause severe disease. The vaccinated animals did not show 
differences in bodily condition after challenge, except that animals in the ConA group showed a 
slight loss in bodily condition 10 days after challenge. The differences between groups was not 
significant (Figure 14).  
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Figure 14. Bodily condition scores (BCS). A score of 3 is considered to be optimal. BCS was 
estimated by operators on the 5 grade scale, based on the shape of the animal and visibility of the 
backbone and hips, with 5 being round overweight pig and 1 being emaciated animal with hips 
and backbone visible.  
 
Bodily Temperature Measurements  
The temperature of all animals ranged from103-104°F at day of challenge and was within 
the normal body temperature range of 101-104oF. Following challenge, temperature 
measurements were carried out every five days. There were no significant differences in body 
temperatures between the unvaccinated and vaccinated animals, except for 1 animal in group 3 
with a temperature of (>105°F) at DPV 38 and 42 and one animal in group 4 with 107°F at 
DPV38. A drop of temperature, which was within the range for normal temperatures, was 
detected in all groups on the day of necropsy (Figure 15).  
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Figure 15. Bodily temperature measurement. The temperature of each pig (n=7) in each group 
was measured prior to challenge and every five days (DPV 38, 42, 47) post-challenge until 
necropsy on DPV 53.  The mean temperature for each group is presented. Group 1 – 
Unvaccinated, Group 2 – Commercial vaccine, Group 3- Construct A, Group 4 – Construct B.  
 
Gross Pathology 
 On necropsy, two pigs from the unvaccinated group were found to have a moderate 
enlargement of the mesenteric lymph while one of them had a patchy atelectasis affecting 
approximately 10% of right cranial and middle lung lobes. No other significant changes were 
noted in the organs of the pigs in the other groups. 
Elisa for the Detection of Diva Antigens 
As expected, animals vaccinated with constructs A and B mounted an anamnestic 
antibody response to the positive marker antigen, GRA6 following the booster at DPV 18, while 
the response of pigs in the groups not immunized with GRA6 (Groups 1 and 2) remained below 
the baseline. The response to the GRA6 antigen increased for the duration of the experiment in 
groups 3 and 4. For the negative NLS marker, as expected, the unvaccinated animals and animals 
vaccinated with Con A and B did not mount an anamnestic response on challenge, while animals 
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which received the commercial vaccine showed a sharp increase in titers. Similarly, the 
unvaccinated animals showed an increase in titer after the challenge, when they were first 
exposed to the negative marker. Reactivity to both antigens was detected at the start of the 
experiment when maternal antibody levels were high (Figure 16
 
Figure 16. Detection of antibody responses to the DIVA antigens. Antibody responses to the 
positive (GRA6) and negative (NLS) markers were measured by ELISA for all four test groups 
(N=7 each). The mean value of two replicate measurements is depicted. Black vertical bar- day 
of booster, red vertical bar – day of challenge. 
 
Detection of Binding Antibody Responses to the Capsid Protein  
Baseline antibody responses to the capsid protein were detected at day 0 in all groups due 
to the presence of maternal antibodies. The maternal antibody responses declined by DPV18. As 
expected, following the booster vaccination, an anamnestic response was mounted in all 
vaccinated groups, with the difference being most apparent in groups which received Con A and 
B.  A further increase was noted in the vaccinated animals post challenge, while the 
unvaccinated animals showed an increase in PCV2-ORF2 specific antibodies a week after the 
challenge (Figure 17). 
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Figure 17. Antibody responses to the PCV2 ORF2 antigen. Antibody responses to the complete 
PCV2 ORF2 antigen was measured by ELISA for all four test groups (N=7 each). The mean 
value of two replicate measurements is depicted. Black vertical bar- day of booster, red vertical 
bar – day of challenge. 
 
Quantification of Viral Loads  
Detection of PCV2 DNA by quantitative real time PCR showed that all animals were 
negative prior to the challenge. All groups were negative prior to challenge. In negative control 
inoculation group 6/7 animals were positive after 10 days post challenge, and 7/7 were positive 
at 17 days post challenge, with average of 104.3 and 105.1 genomes per ml at day post challenge 
10 and 17 correspondingly. Group vaccinated with commercial vaccine had only 2/7 animals 
positive at both time points, but interestingly while animal #14 showed constant viral load at 
days post challenge 10 and 17, animals #11 and #13 were positive at a single time point each: 
#11 at DPI42 and #13 at DPI 39.  Animals vaccinated with construct A and B were all positive 
for PCV2 genomes at both time points (fig 7.). The only statistically significant difference was 
observed between groups vaccinated with Commercial vaccine group if compared to any other 
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group.  There was no statistically significant difference in genome loads between mock 
vaccinated groups and groups immunized with construct A and B. 
 
Figure 18. Detection of viral load by qPCR. The viral loads in the sera of the test animals at 10 
and 17 days’ post challenge in all four groups (N=7 each) were measured by qPCR.  The mean 
of duplicate Ct values, converted into genome copy per ml is depicted. Blue bar indicates 
average value for the group. 
 
Virus Neutralization Assay  
The ability of pre-challenge sera from the test animals to neutralize the viral strain which 
is homologous to the vaccine constructs (PCV2b strain 41513) as measured by a fluorescent 
focus neutralization (FFN) assay, showed that the commercial vaccine induced a percentage FFN 
reduction of 69% while the Con A and B groups had a reduction of 51 and 52% respectively. 
Sera from the unvaccinated pigs showed no reduction, as expected. All groups, except 3 and 4, 
were significantly different from one another (Figure 18). 
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Figure 19. Virus neutralization assay. Pooled sera from all pigs (N=7) in each of the 4 test 
groups; namely, Group 1 – Unvaccinated, Group 2 – commercial vaccine, Group 3- construct A, 
Group 4 – construct B, assessed for virus neutralizing ability by a fluorescent focus inhibition 
assay. The homologous virus strain PCV2b 41513 was used for neutralization.  The mean 
percentage reduction in the number of fluorescent foci in treatment groups compared to the virus 
control is depicted. Bars with similar letters are not significantly different.  
 
Discussion and Future Directions 
Previously published studies on the identification of protective epitopes of PCV2 suggest 
that residues 132 and 146 (Truong et al., 2001) and 157 and 186 (Lekcharoensuk et al., 2004) are 
neutralizing in nature.  Our analysis did not confirmed this findings but rather showed that 
residues 98-103 are responsible for neutralization, and that changes introduced in the current 
study to a capsid protein did not disrupt the neutralizing epitope identified in this study. 
While little published information is available regarding decoy epitopes on the PCV2 
capsid protein, the region 169-180,was identified as a decoy epitope by Tribe et.al.,  (Trible et 
al., 2012) and spanned peptides 56-59. In this study, this region showed a low initial antibody 
response on PEPSCAN analysis and increased immune response by DPI 28 (Fig9) indicating a 
discrepancy between our findings and those of Trible et al. However, the differences can be 
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explained by variations in the immune response of individual animals used in the study, or strain 
specific differences. Based on the PEPSCAN analysis and FFN assays, the strongest decoy 
activity was predicted for peptides 33-38 which corresponds to amino-acid residues 97-123. 
Interestingly, this region also contains a putative receptor binding region (residues 98-103)  
(Meerts et al., 2006; Misinzo et al., 2006). However, decoy epitopes are commonly present 
adjacent to conserved receptor binding sites as steric interference due to antigen antibody 
binding can prevent the binding of neutralizing antibodies to the receptor binding site (Köhler et 
al., 1994). While a limitation of this study is the exact residues involved in the decoy effect were 
not finely mapped, it is likely that the residues within the 97-123 region, which do not form a 
part of the receptor binding site, namely 104-123 are involved in the decoy activity. Hence, 
based on published information and our own analysis, six amino-acid substitutions were 
implemented: E104D, T131N, A133S, Q175N, and K179S to modify the putative decoy 
epitopes. In addition, construct B, would also have deletion of amino-acid residues 170-175, that 
were not shown to be a decoy epitope in our epitope analysis, but were responsible for increase 
in antibody production in a later stages of infection and were previously identified as decoy 
(Trible et al., 2012). 
Since the putative neutralizing epitopes are located in the N term region of the capsid 
protein, a furin cleavage site was introduced between the ORF2 protein and the positive DIVA 
marker, so that antigen processing would not be interfered with. While specific cleavage could 
not be demonstrated in vitro, possibly due to interference with the buffer by the protein 
constituents such as trace amounts of urea, the furin cleavage site has previously been active in-
vivo in swine (Drews et al., 1995). The selection of the positive marker was done on the basis of 
following criteria: it should not be found in swine, sequence and serological data should be 
46 
available, also it would be desired to have antibodies specific to selected protein, to be able to 
confirm its antigenic properties after obtaining of heterologous proteins. Selected epitope of` 
GRA6 of N.caninum satisfied all the conditions in that, N.caninum have not been found in swine, 
it’s sequence and antigenic properties have been described (Baszler et al., 2008; Ramamoorthy et 
al., 2007), and we had polyclonal serum at our disposal for this pathogen. A possible reason for 
cross-reactivity noted in the commercial vaccine group is that the Toxoplasma gondii which is 
sometimes found in swine producing farms has a homologous gene although there is no 
published information that the N. caninum GRA6 protein and the T.gondii GRA6 protein cross-
react serologically due to some degree of amino acid similarity.  
As an alternate strategy, the NLS of the ORF2 protein was removed, as it is known to 
contain a B cell epitope (Lekcharoensuk et al., 2004) but this did not seem to contribute to the 
protective response in our analysis. In group 2, the only group that should have been in contact 
with NLS prior to challenge, a very strong response was detectable after the challenge. Immune 
response to the NLS, was detected in groups 2 and 3 at DPV25 at lower levels. In groups 1 and 4 
the trend of increasing immune response to NLS became evident only 21 days after challenge 
(DPV53), but the response was not strong enough to classify animals as positive. A trend of 
increased response to NLS in group 3 from DPV18 to DPV25 and may indicate that some 
animals had contact with wild PCV2. In fact, only 2 animals out of 7 in group 3 show increase in 
titers of anti-NLS response. Further optimization of the DIVA ELISAs to improve sensitivity and 
specificity will increase the utility of these markers to differentiate infected and vaccinated 
animals.  
While loss of bodily condition and poor weight gain is a hall mark sign of PMWS in the 
field, existing experimental animal models for PCV2 research do not accurately reproduce these 
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signs (Opriessnig et al., 2008b, 2013). The mPCV2b strain used as the challenge strain in this 
study is known to be more virulent under field conditions. However, similar to the scenario when 
PCV2b emerged and in this study, the increased pathogenicity was not demonstrated in 
experimental models (Guo et al., 2011). Previous characterization of the mPCV2b strain in pigs 
showed that the virus replicated to log104± 3.21 copies/ml in infected animals at 10 weeks 
(Opriessnig et al., 2013). However, in this study, very low levels of replication were detected at 
10 and 18 days’ post challenge, cofounding the interpretation of results for the efficacy of Con A 
and B in viral clearance. The dose of 105 TCID50 used in this study is standard for PCV2 
challenge studies (Fenaux et al., 2002; Ramamoorthy et al., 2011). The low levels of viral 
replication are therefore unlikely to be due to a dose effect. However, the examination of 
microscopic lesions between groups may shed a clearer light on vaccine efficacy. 
In this study, the lack of strong viral replication in the unvaccinated controls renders the 
interpretation of viral clearance data difficult. While the commercial vaccine appeared to induce 
immunity in all but two pigs, the level of viral load detection in the ConA and B and 
unvaccinated controls was also extremely low at few hundred viral particles, which would be 
below the 35% margin of error for a TCID50 assay that only detects live virus (Roldão et al., 
2009). Moreover, DNA copy number does not always correlate exactly with the detection of live 
virus; genome copy numbers generally provide for an over-estimation, especially in in vivo 
studies (Gustafsson et al., 2012; Kim et al., 2014). 
Binding antibody response to the PCV2 capsid protein were appropriately detected in all 
groups, following an anamnestic pattern. In confirmation of the hypothesis that amino acid 
residues 160-178 (peptides 56-59) map to an immune-dominant region (Fig 1), pigs exposed to 
Con A in which this region was deleted showed a lower total IgG response to the ORF2 when 
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compared to the other groups. The mPCV2b strain has an additional K in the C terminus of the 
ORF2 where neutralizing epitopes are located (Opriessnig et al., 2014a). However, as one of the 
properties of decoy epitopes is to confer subtle serological differences, which can translate to 
neutralizing properties, between strains, hypothetically, a vaccine with changed decoy epitopes 
should induce wider protection against different serotypes. Although the V/N titers were less 
than those generated by immunization with the commercial vaccine, pigs immunized with ConA 
and B had significant V/N titers for the homologous PCV2b strain 41513. The exact parameters 
by which a vaccine induces sterilizing immunity is not well understood. It is possible that 
additional 20% reduction as measured by the FFN assay could be sufficient to overcome the 
threshold of balance between pathogen and immune system that would translate in to protection 
in-vivo. Virus neutralization titers against other heterologous virus strains remain to be tested. 
In conclusion, the successful addition of the DIVA markers provides an enhanced 
capability to existing PCV2 vaccines, which is likely to improve vaccine compliance and 
monitoring capability in the field level. Moreover, the developed vaccines are the only DIVA 
capable vaccines available in the U.S and are likely targets for deployment in a national PCV2 
eradication plan. While more sophisticated testing at the epitope level is required to demonstrate 
the efficacy of the immune-refocusing strategy used in this study, the performance of the 
developed vaccines was comparable to the commercial vaccine, especially for weight gain 
parameters for ConB vaccinated pigs which was significantly higher than the commercial 
vaccine. 
While the more sophisticated testing at the epitope level is required to demonstrate the 
efficacy of the immune-refocusing strategy used in this study, the performance of the developed 
vaccines was only marginally lower compared to the commercial vaccine. However, as the 
49 
details of vaccine formulation for the commercial vaccine are unknown, an objective comparison 
cannot be drawn. Additional testing with a more virulent challenge strain and increased number 
of animals is the focus of the next phase of vaccine testing. 
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